• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

BUPRENORPHINE Drug Record

  • Summary
  • Interactions
  • Claims
  • BUPRENORPHINE chembl:CHEMBL511142 Approved

    Alternate Names:

    TEPHINE
    BUPEAZE
    PRENOTRIX
    BUTEC
    BUTRANS
    BUPLAST
    RELETRANS
    ALKS-5461 COMPONENT BUPRENORPHINE
    SUBLOCADE
    TEMGESIC
    SEVODYNE
    TRANSTEC
    PANITAZ
    BUPRENORPHINE
    HAPOCTASIN

    Drug Info:

    Drug Class Small Molecule
    FDA Approval approved
    Drug Class Small molecule
    Drug Indications antidepressant,analgesic,for treatment of opioid addiction
    Drug Class analgesics, opioid
    Year of Approval 1981
    (2 More Sources)

    Publications:

    Crist RC et al., 2018, Pharmacogenetic analysis of opioid dependence treatment dose and dropout rate., Am J Drug Alcohol Abuse
    Zanger UM et al., 2008, Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation., Anal Bioanal Chem
    Sánchez-Blázquez et al., 2001, Agonists determine the pattern of G-protein activation in mu-opioid receptor-mediated supraspinal analgesia., Brain Res. Bull.
    Kishioka et al., 2000, Buprenorphine and methoclocinnamox: agonist and antagonist effects on respiratory function in rhesus monkeys., Eur. J. Pharmacol.
    Ide et al., 2004, Buprenorphine antinociception is abolished, but naloxone-sensitive reward is retained, in mu-opioid receptor knockout mice., Neuropsychopharmacology
    Zubieta et al., 2000, Buprenorphine-induced changes in mu-opioid receptor availability in male heroin-dependent volunteers: a preliminary study., Neuropsychopharmacology
    Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
    Mizoguchi et al., 2002, Antagonistic property of buprenorphine for putative epsilon-opioid receptor-mediated G-protein activation by beta-endorphin in pons/medulla of the mu-opioid receptor knockout mouse., Neuroscience
    Muriel J et al., 2019, Pharmacogenetics and prediction of adverse events in prescription opioid use disorder patients., Basic Clin Pharmacol Toxicol
    Sastre JA et al., 2015, Influence of uridine diphosphate-glucuronyltransferase 2B7 (UGT2B7) variants on postoperative buprenorphine analgesia., Pain Pract
    Crist RC et al., 2019, Replication of the pharmacogenetic effect of rs678849 on buprenorphine efficacy in African-Americans with opioid use disorder., Pharmacogenomics J
    Clarke TK et al., 2014, Genetic variation in OPRD1 and the response to treatment for opioid dependence with buprenorphine in European-American females., Pharmacogenomics J
    Crist RC et al., 2013, An intronic variant in OPRD1 predicts treatment outcome for opioid dependence in African-Americans., Neuropsychopharmacology
    Lester et al., 2006, Comparison of the in vitro efficacy of mu, delta, kappa and ORL1 receptor agonists and non-selective opioid agonists in dog brain membranes., Brain Res.
    Induru et al., Buprenorphine for neuropathic pain--targeting hyperalgesia., Am J Hosp Palliat Care
    Mégarbane et al., 2006, Buprenorphine is protective against the depressive effects of norbuprenorphine on ventilation., Toxicol. Appl. Pharmacol.
    Boothby et al., 2007, Buprenorphine for the treatment of opioid dependence., Am J Health Syst Pharm
    Robinson, 2006, Buprenorphine-containing treatments: place in the management of opioid addiction., CNS Drugs
    Ettienne EB et al., 2019, Pharmacogenomics and Opioid Use Disorder: Clinical Decision Support in an African American Cohort., J Natl Med Assoc
    Blanco F et al., 2016, Influence of UGT2B7, CYP3A4, and OPRM1 Gene Polymorphisms on Transdermal Buprenorphine Pain Control in Patients with Critical Lower Limb Ischemia Awaiting Revascularization., Pain Pract
  • BUPRENORPHINE   ARRB2

    Interaction Score: 3.09

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    30549211


    Sources:
    PharmGKB

  • BUPRENORPHINE   PNOC

    Interaction Score: 3.09

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • BUPRENORPHINE   OPRD1

    Interaction Score: 1.36

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Trial Name V1003
    Novel drug target Established target
    Trial Name ALKS 5461

    PMIDs:
    30549211 30368523 24126707 23612435 16443205 19666890 16169027


    Sources:
    TdgClinicalTrial PharmGKB

  • BUPRENORPHINE   OPRM1

    Interaction Score: 0.65

    Interaction Types & Directionality:
    partial agonist (activating)
    agonist (activating)

    Interaction Info:
    Trial Name V1003
    Trial Name CAM2038
    Trial Name Butrans is a transdermal patch formulation of buprenorphine, a partial agonist at mu opioid receptors and an antagonist at kappa opioid receptors. It is indicated as an analgesic to deliver continuous pain relief for seven days. The efficacy of Butrans

    PMIDs:
    11275413 10729371 15100703 10942856 11752352 12435410 30549211


    Sources:
    TdgClinicalTrial ChemblInteractions TEND PharmGKB

  • BUPRENORPHINE   UGT2B7

    Interaction Score: 0.59

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    24256307


    Sources:
    PharmGKB

  • BUPRENORPHINE   OPRK1

    Interaction Score: 0.45

    Interaction Types & Directionality:
    agonist (activating)
    antagonist (inhibitory)

    Interaction Info:
    Mechanism of Interaction Kappa opioid receptor agonist
    Direct Interaction yes
    Trial Name ALKS 5461

    PMIDs:
    17244875 16953647


    Sources:
    TdgClinicalTrial ChemblInteractions TEND

  • BUPRENORPHINE   COMT

    Interaction Score: 0.39

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    30549211


    Sources:
    PharmGKB

  • BUPRENORPHINE   SLC6A4

    Interaction Score: 0.24

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    29333880


    Sources:
    PharmGKB

  • BUPRENORPHINE   CYP3A5

    Interaction Score: 0.12

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    18695978


    Sources:
    PharmGKB

  • BUPRENORPHINE   CYP3A4

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    31676110 26407542


    Sources:
    PharmGKB

  • TdgClinicalTrial: BUPRENORPHINE

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications antidepressant,analgesic,for treatment of opioid addiction
    Drug Class Small molecule
    FDA Approval approved

    Publications:

  • TEND: BUPRENORPHINE

    • Version: 01-August-2011

    Alternate Names:

    Drug Info:
    Year of Approval 1981
    Drug Class analgesics, opioid

    Publications:

  • PharmGKB: buprenorphine

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    Crist RC et al., 2018, Pharmacogenetic analysis of opioid dependence treatment dose and dropout rate., Am J Drug Alcohol Abuse
    Zanger UM et al., 2008, Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation., Anal Bioanal Chem
    Sastre JA et al., 2015, Influence of uridine diphosphate-glucuronyltransferase 2B7 (UGT2B7) variants on postoperative buprenorphine analgesia., Pain Pract

  • TTD: Buprenorphine

    • Version: 2020.06.01

    Alternate Names:
    D06AWE TTD Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL511142

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

  • ChemblInteractions: CHEMBL511142

    • Version: chembl_23

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21